View : 15 Download: 0
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
- Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
- Lee, Sung-Eun; Choi, Soo Young; Song, Hye-Young; Kim, Soo-Hyun; Choi, Mi-Yeon; Park, Joon Seong; Kim, Hyeoung-Joon; Kim, Sung-Hyun; Zang, Dae Young; Oh, Sukjoong; Kim, Hawk; Do, Young Rok; Kwak, Jae-Yong; Kim, Jeong-A; Kim, Dae-Young; Mun, Yeung-Chul; Lee, Won Sik; Chang, Myung Hee; Park, Jinny; Kwon, Ji Hyun; Kim, Dong-Wook
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- vol. 101, no. 6, pp. 717 - 723
- FERRATA STORTI FOUNDATION
- SCI; SCIE; SCOPUS
- The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total of 90 patients with a follow-up of >= 12 months were analyzed. After a median follow-up of 26.6 months after imatinib discontinuation, 37 patients lost the major molecular response. The probability of sustained major molecular response at 12 months and 24 months was 62.2% and 58.5%, respectively. All 37 patients who lost major molecular response were retreated with imatinib therapy for a median of 16.9 months, and all achieved major molecular response again at a median of 3.9 months after resuming imatinib therapy. We observed newly developed or worsened musculoskeletal pain and pruritus in 27 (30%) patients after imatinib discontinuation. Imatinib withdrawal syndrome was associated with a higher probability of sustained major molecular response (P=0.003) and showed a trend for a longer time to major molecular response loss (P=0.098). Positivity (defined as >= 17 positive chambers) of digital polymerase chain reaction at screening and longer imatinib duration before imatinib discontinuation were associated with a higher probability of sustained major molecular response. Our data demonstrated that the occurrence of imatinib withdrawal syndrome after imatinib discontinuation and longer duration of imatinib were associated with a lower rate of molecular relapse. In addition, minimal residual leukemia measured by digital polymerase chain reaction had a trend for a higher molecular relapse.
- Appears in Collections:
- 의학전문대학원 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.